Eidelman Virant Capital Ocuphire Pharma, Inc. Transaction History
Eidelman Virant Capital
- $136 Million
- Q3 2022
A detailed history of Eidelman Virant Capital transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Eidelman Virant Capital holds 25,000 shares of OCUP stock, worth $24,500. This represents 0.04% of its overall portfolio holdings.
Number of Shares
25,000
Previous 25,000
-0.0%
Holding current value
$24,500
Previous $48,000
6.25%
% of portfolio
0.04%
Previous 0.03%
Shares
1 transactions
Others Institutions Holding OCUP
# of Institutions
47Shares Held
5.21MCall Options Held
12.6KPut Options Held
1.8K-
Bios Capital Management, LP Fort Worth, TX2.48MShares$2.43 Million3.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA992KShares$972,3560.0% of portfolio
-
Geode Capital Management, LLC Boston, MA314KShares$307,7040.0% of portfolio
-
Voss Capital, LLC Houston, TX191KShares$187,1380.02% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il176KShares$172,2570.0% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $20.2M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...